Indications for use of Kagocel are:

Kagocel is used in adults as a preventive and therapeutic agent for influenza and other respiratory viral infections, as well as a therapeutic agent for herpes.

Pharmachologic effect:

The main mechanism of action of Kagocel is the ability to induce the production of interferon. Kagocel causes the formation in the human body of the so-called late interferon, which is a mixture of alpha and beta interferons with high antiviral activity. Kagocel induces the production of interferon in almost all populations of cells involved in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel is taken orally, the interferon titer in the blood serum reaches its maximum values ​​after 48 hours. The body's interferon response to the introduction of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of the accumulation of interferon in the intestine when ingested Kagocel does not coincide with the dynamics of the titers of circulating interferon. In the blood serum, interferon production reaches high values ​​only 48 hours after taking Kagocel, while in the intestine, the maximum interferon production is noted already after 4 hours. Kagocel, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not possess mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect. The greatest efficiency in the treatment of Kagocel is achieved when it is administered no later than the 4th day after the onset of an acute infection. For prophylactic purposes, the drug can be used at any time, including immediately after contact with the infectious agent. The drug is excreted from the body mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% with feces and 10% with urine.